STOKE THERAPEUTICS INC's ticker is STOK and the CUSIP is 86150R107. A total of 90 filers reported holding STOKE THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $278,357 | +27.6% | 26,186 | 0.0% | 0.00% | – |
| Q1 2023 | $218,129 | -9.8% | 26,186 | 0.0% | 0.00% | – |
| Q4 2022 | $241,697 | -29.1% | 26,186 | 0.0% | 0.00% | – |
| Q3 2022 | $341,000 | -25.7% | 26,186 | -24.6% | 0.00% | -100.0% |
| Q2 2022 | $459,000 | -37.2% | 34,714 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $731,000 | -12.2% | 34,714 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $833,000 | +12.4% | 34,714 | +19.2% | 0.00% | 0.0% |
| Q3 2021 | $741,000 | -11.2% | 29,114 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $834,000 | -42.0% | 29,114 | -21.3% | 0.00% | -50.0% |
| Q1 2021 | $1,438,000 | -25.9% | 37,014 | +18.1% | 0.00% | 0.0% |
| Q4 2020 | $1,941,000 | +160.2% | 31,341 | +40.7% | 0.00% | +100.0% |
| Q3 2020 | $746,000 | +40.5% | 22,279 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $531,000 | +4.1% | 22,279 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $510,000 | -9.4% | 22,279 | +12.1% | 0.00% | 0.0% |
| Q4 2019 | $563,000 | +31.9% | 19,879 | 0.0% | 0.00% | 0.0% |
| Q3 2019 | $427,000 | – | 19,879 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ATP Life Science Ventures, L.P. | 17,161,713 | $1,062,825,000 | 82.06% |
| RTW INVESTMENTS, LP | 3,544,248 | $219,495,000 | 3.68% |
| Cormorant Asset Management, LP | 1,437,807 | $89,043,000 | 2.12% |
| Redmile Group, LLC | 2,686,234 | $166,358,000 | 2.01% |
| ACUTA CAPITAL PARTNERS, LLC | 92,500 | $5,729,000 | 1.56% |
| Pinz Capital Management, LP | 34,200 | $2,118,000 | 0.96% |
| Birchview Capital, LP | 20,000 | $1,239,000 | 0.71% |
| HighVista Strategies LLC | 17,668 | $1,094,000 | 0.70% |
| GILDER GAGNON HOWE & CO LLC | 1,470,841 | $91,089,000 | 0.45% |
| Perceptive Advisors | 671,978 | $41,616,000 | 0.45% |